Summary In 2018, the US National Institute on Aging and the Alzheimer's Association
proposed a purely biological definition of Alzheimer's disease that relies on biomarkers …

A growing awareness about brain health and Alzheimer's disease in the general population
is leading to an increasing number of cognitively unimpaired individuals, who are concerned …

Various biomarkers are available to support the diagnosis of neurodegenerative diseases in
clinical and research settings. Among the molecular imaging biomarkers, amyloid-PET …

China's population has rapidly aged over the recent decades of social and economic
development as neurodegenerative disorders have proliferated, especially Alzheimer's …

Subjective cognitive decline (SCD) is regarded as the first clinical manifestation in the
Alzheimer's disease (AD) continuum. Investigating populations with SCD is important for …

Transcranial magnetic stimulation (TMS) is a powerful tool to probe in vivo brain circuits, as it
allows to assess several cortical properties such as excitability, plasticity and connectivity in …

Alzheimer's disease (AD) is a degenerative neurological disease in elderly individuals.
Subjective cognitive decline (SCD), mild cognitive impairment (MCI) and further …

Background Serum glial fibrillary acidic protein (GFAP) and neurofilament light (NfL) are
putative non-amyloid blood-based biomarkers indicative of ongoing inflammatory and …

Importance The behavioral variant of Alzheimer disease (bvAD) is characterized by early
and predominant behavioral deficits caused by AD pathology. This AD phenotype is …

Cognitive symptoms are common, and yet many who seek help for cognitive symptoms
neither have, nor go on to develop, dementia. A proportion of these people are likely to have …